Annual report [Section 13 and 15(d), not S-K Item 405]

Revenue (Details)

v3.25.1
Revenue (Details) - USD ($)
 3 Months Ended 12 Months Ended
Jul. 01, 2021
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Disaggregation of Revenue [Line Items]        
Total revenues, net     $ 441,000 $ 1,924,000
Other receivables   $ 136,000 611,000 136,000
Product revenue, net        
Disaggregation of Revenue [Line Items]        
Total revenues, net     441,000 1,408,000
License and other revenue        
Disaggregation of Revenue [Line Items]        
Total revenues, net     0 $ 516,000
Major Customer One | Sales Revenue | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Concentration risk       58.00%
Major Customer Two | Sales Revenue | Customer Concentration Risk        
Disaggregation of Revenue [Line Items]        
Concentration risk       42.00%
Millipred        
Disaggregation of Revenue [Line Items]        
Percent of net profit for installment payments 50.00%      
Installment payments $ 500,000      
License agreement, term 25 months      
Retention amount     1,000,000  
Other receivables     500,000  
AUG Therapeutics, LLC | Purchase Agreement        
Disaggregation of Revenue [Line Items]        
Upfront payment paid   200,000    
Asset acquisition consideration transferred, liabilities   $ 400,000    
AUG Therapeutics, LLC | License and other revenue | Purchase Agreement        
Disaggregation of Revenue [Line Items]        
Total revenues, net     $ 0 $ 500,000